Literature DB >> 16553764

Health-related quality of life among haemodialysis patients--relationship with clinical indicators, morbidity and mortality.

Cássia Maria Morsch1, Luiz Felipe Gonçalves, Elvino Barros.   

Abstract

AIM: To verify the association between quality of life and morbidity, mortality and clinical indicators in haemodialysis patients.
BACKGROUND: While a number of therapies have been reported to increase quality of life in end-stage renal disease, patients report that they remain substantially burdened by limited physical functioning and by dialysis-related symptoms. Indeed, quality of life may be the most critical outcome for those undergoing haemodialysis. Furthermore, quality of life has been associated with clinical indicators, morbidity and survival in haemodialysis patients.
DESIGN: Descriptive cohort study of patients undergoing haemodialysis at the Nephrology Hemodialysis Unit of the Hospital de Clínicas in Porto Alegre, Brazil.
METHODS: Forty haemodialysis patients were followed for 12 months and evaluated for demographics, time on dialysis, diabetes mellitus, clinical indicators (dose of dialysis--Kt/V, haematocrit and serum albumin) and comorbidities. The comorbidities were evaluated with the end-stage renal disease severity index and health-related quality of life with The Medical Outcomes Study 36 (SF-36).
RESULTS: Men present higher health-related quality of life scores in the energy and fatigue component (P = 0.04). Patients treated for over one year at the beginning of follow up and patients with less schooling had better results in General Health Perception (P < 0.05). The health-related quality of life evaluation of patients who later died showed that they already had a worse perception of physical functioning as compared to the survivors (P = 0.05). Patients with diagnosed diabetes perceived their physical functioning more negatively compared with those with other etiologies of end-stage renal disease (P = 0.045). We found a correlation between physical functioning and serum albumin (r = 0.341, P < 0.05) and between physical functioning and haematocrit (r = 0.317, P < 0.05). The end-stage renal disease severity index was more strongly related to physical functioning (r = -0.538, P < 0.001). Comparing the patients' results to the indicators above and below the established targets, we observed a trend to worse health-related quality of life in patients with Kt/V above target. However, in the case of albumin, patients with results above target tended to have better results.
CONCLUSION: A close relationship was observed between quality of life and morbidity and mortality. Among the clinical indicators, albumin and haematocrit have the greatest influence on quality of life. RELEVANCE TO CLINICAL PRACTICE: Haemodialysis patients experience various problems that may adversely influence their quality of life. Special care must be given to those who have diabetes mellitus, high morbidity scores, low serum albumin and low haematocrits.

Entities:  

Mesh:

Year:  2006        PMID: 16553764     DOI: 10.1111/j.1365-2702.2006.01349.x

Source DB:  PubMed          Journal:  J Clin Nurs        ISSN: 0962-1067            Impact factor:   3.036


  25 in total

1.  Quality of life of patients in renal replacement therapy in Brazil: comparison of treatment modalities.

Authors:  Juliana Alvares; Cibele Comini Cesar; Francisco de Assis Acurcio; Eli Iola Gurgel Andrade; Mariangela Leal Cherchiglia
Journal:  Qual Life Res       Date:  2011-09-22       Impact factor: 4.147

2.  The associations of hemodialysis access type and access satisfaction with health-related quality of life.

Authors:  Natalie Domenick Sridharan; Larry Fish; Lan Yu; Steven Weisbord; Manisha Jhamb; Michel S Makaroun; Theodore H Yuo
Journal:  J Vasc Surg       Date:  2017-08-16       Impact factor: 4.268

3.  Predictors of health-related quality of life perceived by end-stage renal disease patients under online hemodiafiltration.

Authors:  Alexandra Moura; José Madureira; Pablo Alija; João Carlos Fernandes; José Gerardo Oliveira; Martin Lopez; Madalena Filgueiras; Leonilde Amado; Maria Sameiro-Faria; Vasco Miranda; Edgar Mesquita; Alice Santos-Silva; Elísio Costa
Journal:  Qual Life Res       Date:  2014-11-08       Impact factor: 4.147

Review 4.  Fatigue in patients with diabetes: a review.

Authors:  Cynthia Fritschi; Laurie Quinn
Journal:  J Psychosom Res       Date:  2010-03-23       Impact factor: 3.006

5.  A comparison of SF-36 and SF-12 composite scores and subsequent hospitalization and mortality risks in long-term dialysis patients.

Authors:  Eduardo Lacson; Jianglin Xu; Shu-Fang Lin; Sandie Guerra Dean; J Michael Lazarus; Raymond M Hakim
Journal:  Clin J Am Soc Nephrol       Date:  2009-12-17       Impact factor: 8.237

Review 6.  Biomarkers and health-related quality of life in end-stage renal disease: a systematic review.

Authors:  Brennan M R Spiegel; Gil Melmed; Sean Robbins; Eric Esrailian
Journal:  Clin J Am Soc Nephrol       Date:  2008-10-01       Impact factor: 8.237

7.  Quality of life assessment among haemodialysis patients in a single centre: a 2-year follow-up.

Authors:  Paulo R Santos; Elizabeth F Daher; Geraldo B Silva; Alexandre B Libório; Ligia R Kerr
Journal:  Qual Life Res       Date:  2009-04-11       Impact factor: 4.147

8.  A Comparison of Temporal Patterns of Fatigue in Patients on Hemodialysis.

Authors:  Ann E Horigan; Julie V Barroso
Journal:  Nephrol Nurs J       Date:  2016 Mar-Apr       Impact factor: 0.959

9.  Psychosocial and Clinical Correlates of Fatigue in Haemodialysis Patients: the Importance of Patients' Illness Cognitions and Behaviours.

Authors:  Joseph Chilcot; Rona Moss-Morris; Micol Artom; Larissa Harden; Federica Picariello; Hector Hughes; Sarah Bates; Iain C Macdougall
Journal:  Int J Behav Med       Date:  2016-06

10.  Correlates and outcomes of fatigue among incident dialysis patients.

Authors:  Manisha Jhamb; Christos Argyropoulos; Jennifer L Steel; Laura Plantinga; Albert W Wu; Nancy E Fink; Neil R Powe; Klemens B Meyer; Mark L Unruh
Journal:  Clin J Am Soc Nephrol       Date:  2009-10-01       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.